EndoChoice Holdings, Inc. is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems. The Company's products are used in colonoscopy and procedures of the upper GI tract, including esophagogastroduodenoscopy (EGD). The Company's imaging products include Fuse system, EndoCart, and Endoscope repair and maintenance. The Company's single-use therapeutic devices include Neptune injection needle, Boa polypectomy snare, Rescue retrieval devices, Blox bite block, TrapEase polyp traps, Hydra irrigation system, EndoGlide+, Compliance EndoKit, SafeStart, EndoKit, CinchPad and GI pathology. The Company serves over 2,500 GI departments that perform endoscopic procedures.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Medical Imaging Systems
- Sub-Industry: N/A
- Symbol: NYSE:GI
- CUSIP: N/A
- Web: www.endochoice.com
- 50 Day Moving Avg: $8.00
- 200 Day Moving Avg: $7.14
- 52 Week Range: $3.64 - $8.03
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.35
- P/E Growth: 0.00
- Net Margins: -90.67%
- Return on Equity: -130.29%
- Return on Assets: -60.59%
- Debt-to-Equity Ratio: 0.93%
- Current Ratio: 3.95%
- Quick Ratio: 3.09%
Frequently Asked Questions for EndoChoice Holdings (NYSE:GI)
What is EndoChoice Holdings' stock symbol?
EndoChoice Holdings trades on the New York Stock Exchange (NYSE) under the ticker symbol "GI."
How were EndoChoice Holdings' earnings last quarter?
EndoChoice Holdings Inc (NYSE:GI) posted its earnings results on Wednesday, May, 4th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.13. The firm had revenue of $18.46 million for the quarter, compared to analysts' expectations of $18.34 million. EndoChoice Holdings had a negative return on equity of 130.29% and a negative net margin of 90.67%. The firm's revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company posted ($1.00) EPS. View EndoChoice Holdings' Earnings History.
Who are some of EndoChoice Holdings' key competitors?
Some companies that are related to EndoChoice Holdings include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), VCA (WOOF), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC), ConvaTec Group PLC (CTEC), Health Net (HNT), Catalent (CTLT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Puma Biotechnology (PBYI), Cotiviti Holdings (COTV) and WuXi PharmaTech (Cayman) (WX).
When did EndoChoice Holdings IPO?
(GI) raised $101 million in an initial public offering (IPO) on Friday, June 5th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, BofA Merrill Lynch, William Blair and Stifel served as the underwriters for the IPO.
How do I buy EndoChoice Holdings stock?
Shares of EndoChoice Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is EndoChoice Holdings' stock price today?
MarketBeat Community Rating for EndoChoice Holdings (NYSE GI)MarketBeat's community ratings are surveys of what our community members think about EndoChoice Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of EndoChoice Holdings stock can currently be purchased for approximately $8.00.
Earnings History for EndoChoice Holdings (NYSE:GI)Earnings History by Quarter for EndoChoice Holdings (NYSE GI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/4/2016||Q116||($0.55)||($0.68)||$18.34 million||$18.46 million||View||N/A|
|3/3/2016||Q415||($0.58)||($0.53)||$19.05 million||$18.50 million||View||N/A|
|11/5/2015||Q315||($0.54)||($0.47)||$18.42 million||$18.40 million||View||N/A|
|8/6/2015||Q215||($0.85)||($0.60)||$17.59 million||$18.60 million||View||N/A|
Earnings Estimates for EndoChoice Holdings (NYSE:GI)
2017 EPS Consensus Estimate: ($2.00)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for EndoChoice Holdings (NYSE:GI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for EndoChoice Holdings (NYSE:GI)
Insider Ownership Percentage: 31.50%Insider Trades by Quarter for EndoChoice Holdings (NYSE:GI)
Institutional Ownership Percentage: 37.32%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/16/2016||Mark Gilreath||CEO||Buy||20,000||$5.06||$101,200.00|| |
|3/15/2016||Mark Gilreath||CEO||Buy||5,018||$5.02||$25,190.36|| |
|3/11/2016||David L Kaufman||Director||Buy||89,450||$4.81||$430,254.50|| |
|3/10/2016||David N Gill||CFO||Buy||2,000||$4.70||$9,400.00|| |
|3/10/2016||William R Enquist||Director||Buy||10,000||$4.74||$47,400.00|| |
|3/8/2016||J Scott Carter||Director||Buy||21,600||$4.72||$101,952.00|| |
|3/7/2016||David N Gill||CFO||Buy||5,000||$4.77||$23,850.00|| |
Headline Trends for EndoChoice Holdings (NYSE:GI)
Latest Headlines for EndoChoice Holdings (NYSE:GI)
|Head-To-Head Comparison: EndoChoice Holdings (NYSE:GI) and Novadaq Technologies (NVDQ)|
www.americanbankingnews.com - July 30 at 7:43 AM
|Comparing EndoChoice Holdings (GI) & Analogic Corporation (ALOG)|
www.americanbankingnews.com - July 20 at 9:14 AM
|Critical Contrast: EndoChoice Holdings (GI) & Analogic (ALOG)|
www.americanbankingnews.com - June 26 at 12:10 AM
|EndoChoice Holdings (GI) versus NxStage Medical (NXTM) Critical Contrast|
www.americanbankingnews.com - June 15 at 7:50 AM
|NxStage Medical (NXTM) versus EndoChoice Holdings (GI) Head-To-Head Review|
www.americanbankingnews.com - June 6 at 12:04 PM
|ENDOCHOICE HOLDINGS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting|
biz.yahoo.com - November 22 at 5:03 PM
|Boston Scientific Closes EndoChoice Acquisition - PR Newswire (press release)|
www.prnewswire.com - November 22 at 8:41 AM
|Boston Scientific Closes EndoChoice Acquisition|
finance.yahoo.com - November 22 at 8:41 AM
|ENDOCHOICE HOLDINGS, INC. Financials|
finance.yahoo.com - November 16 at 5:29 PM
|ENDOCHOICE HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - November 8 at 12:08 AM
|Boston Scientific Announces Extension of the Cash Tender Offer for All Shares of EndoChoice - PR Newswire (press release)|
www.prnewswire.com - November 4 at 10:05 PM
|Boston Scientific Announces Extension of the Cash Tender Offer for All Shares of EndoChoice|
finance.yahoo.com - November 4 at 6:41 AM
|Boston Scientific Raises Full-Year Outlook|
www.wsj.com - October 27 at 9:52 AM
|4 Medical Device Stocks on a Bull Run this Earnings Season|
finance.yahoo.com - October 26 at 5:16 PM
|Boston Scientific Announces Results For Third Quarter 2016|
finance.yahoo.com - October 26 at 8:20 AM
|ENDOCHOICE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of EndoChoice Holdings, …|
finance.yahoo.com - October 8 at 9:49 AM
|ENDOCHOICE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of EndoChoice Holdings, Inc. (GI) Over the Proposed Sale of the Company to Boston Scientific Corporation|
finance.yahoo.com - October 8 at 9:49 AM
|Boston Scientific Commences Cash Tender Offer For All Shares Of EndoChoice For $8.00 Per Share In Cash|
finance.yahoo.com - October 7 at 10:11 AM
|SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of EndoChoice Holdings, Inc. And Encourages Investors To Contact The Firm For Additional ...|
www.businesswire.com - October 1 at 4:46 PM
|SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of EndoChoice Holdings ... - Business Wire (press release)|
www.businesswire.com - September 30 at 5:29 PM
EndoChoice Holdings (GI) Chart for Sunday, September, 24, 2017